Ontology highlight
ABSTRACT: Background
Vasoactive intestinal peptide (VIP) exerts immune-modulatory actions mainly via VPAC1 receptor stimulation. VPAC1 may be a treatment target of inflammatory diseases, but little is known about the receptor expression profile in immune-competent cells in vivo.Material and methods
20 male healthy subjects received a single intravenous bolus of 2 ng/kg body weight Escherichia coli endotoxin (LPS). Receptor status was evaluated in peripherial blood cells before and 3, 6 and 24 h after LPS by FACS analysis and q-PCR. VIP plasma concentrations were measured by ELISA.Results
Granulocytes accounted for 51% of leukocytes at baseline and 58?±?37% were positive for VPAC1. The granulocyte population increased 2.6 fold after LPS, and a transient down-regulation of VPAC1 to 28?±?23% was noted at 3 h (p?ConclusionThe time profile of VPAC receptor expression differs in granulocytes, monocytes and lymphocytes after LPS challenge in humans. Changes in circulating VIP concentrations may reflect innate immune responses.
SUBMITTER: Storka A
PROVIDER: S-EPMC3651401 | biostudies-literature | 2013 May
REPOSITORIES: biostudies-literature
Storka Angela A Burian Bernhard B Führlinger Gerhard G Clive Breanna B Sun Terri T Crevenna Richard R Gsur Andrea A Mosgöller Wilhelm W Wolzt Michael M
Journal of translational medicine 20130507
<h4>Background</h4>Vasoactive intestinal peptide (VIP) exerts immune-modulatory actions mainly via VPAC1 receptor stimulation. VPAC1 may be a treatment target of inflammatory diseases, but little is known about the receptor expression profile in immune-competent cells in vivo.<h4>Material and methods</h4>20 male healthy subjects received a single intravenous bolus of 2 ng/kg body weight Escherichia coli endotoxin (LPS). Receptor status was evaluated in peripherial blood cells before and 3, 6 and ...[more]